Rheumatology International

, Volume 27, Issue 3, pp 251–256 | Cite as

Pamidronate and osteoporosis prevention in liver transplant recipients

  • Pietra Pennisi
  • Andrea Trombetti
  • Emiliano Giostra
  • Gilles Mentha
  • René Rizzoli
  • Carmelo E. Fiore
Original Article


Osteoporosis is a common complication in patients with end-stage liver disease and after orthotopic liver transplantation (LT), with resulting increasing fracture rate. In this study, we investigated the role of treatment with pamidronate in preventing further bone loss after LT. Eighty-five patients with end-stage liver disease were included in the study. Pamidronate 30 mg was given intravenously every 3 months after LT for the duration of 1 year to 43 patients with osteopenia or osteoporosis prior LT. The remainders served as controls. All patients received a supplementation of calcium and vitamin D. Bone mineral density (BMD) at the lumbar spine and the femoral neck, and markers of bone metabolism were measured before and 12 months after LT. Sixty-two BMD were available at 12 months; only paired BMD were evaluated. A significant increase in lumbar spine BMD was observed in pamidronate treated patients. No change was evident in controls. Femoral neck BMD decreased in both treated and untreated patients. Osteocalcin serum levels and deoxypyridinoline urinary excretion were significantly reduced by treatment. Our study suggests that pamidronate decreases bone turnover and is effective in preventing the course of bone loss after LT, however the efficacy, at the dosage regimen employed and in a follow-up of 12 months, appears to be limited to trabecular bone, with no effect on the cortical structure of the femur.


Liver transplantation Bone mineral density Cortical bone loss Bone turnover Pamidronate 


  1. 1.
    Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R (2001) Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357:342–347PubMedCrossRefGoogle Scholar
  2. 2.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodes J, Munoz-Gomez J (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148–154PubMedCrossRefGoogle Scholar
  3. 3.
    Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ (1997) Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 103:197–207PubMedCrossRefGoogle Scholar
  4. 4.
    Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R (2000) Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 19:736–743PubMedCrossRefGoogle Scholar
  5. 5.
    Mikuls TR, Julian BA, Bartolucci A, Saag KG (2003) Bone mineral density changes within six months of renal transplantation. Transplantation 75:49–54PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, Mc Closkey E, Mellstrom D, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  7. 7.
    Abdelhadi M, Ericzon BG, Hultenby K, Sjoden G, Reinholt FP, Nordenstrom J (2002) Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus. Transpl Int 15:180–187PubMedCrossRefGoogle Scholar
  8. 8.
    Bikle DD, Sakata T, Halloran BP (2003) The impact of skeletal unloading on bone formation. Gravit Space Biol Bull 16:45–54PubMedGoogle Scholar
  9. 9.
    Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP (1997) Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 61:266–271PubMedCrossRefGoogle Scholar
  10. 10.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299Google Scholar
  11. 11.
    Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 11:960–966PubMedCrossRefGoogle Scholar
  12. 12.
    Riemens SC, Oostdijk A, van Doormaal JJ, Thijn CJ, Drent G, Piers DA, Groen EW, Meerman L, Slooff MJ, Haagsma EB (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporos Int 6:213–218Google Scholar
  13. 13.
    Fan SL, Almond MK, Ball E, Evans K, Cunningham J (2000) Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684–690PubMedGoogle Scholar
  14. 14.
    Bianda T, Linka A, Junga G, Brunner H, Steinert H, Kiowski W, Schmid C (2000) Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67:116–121PubMedCrossRefGoogle Scholar
  15. 15.
    Reeves HL, Francis RM, Manas DM, Hudson M, Day CP (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404–409PubMedCrossRefGoogle Scholar
  16. 16.
    Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37:93–100PubMedCrossRefGoogle Scholar
  17. 17.
    Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82–89PubMedCrossRefGoogle Scholar
  18. 18.
    Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P (2001) Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 12:112–116PubMedCrossRefGoogle Scholar
  19. 19.
    Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA (1991) Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporos Int 1:129–133PubMedCrossRefGoogle Scholar
  20. 20.
    Giannini S, Nobile M, Ciuffreda M, Iemmolo RM, Dalle Carbonare L, Minicuci N, Casagrande F, Destro C, Gerunda GE, Sartori L, Crepaldi G (2000) Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 11:417–424PubMedCrossRefGoogle Scholar
  21. 21.
    Vedi S, Ninkovic M, Garrahan NJ, Alexander GJ, Compston JE (2002) Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. Transpl Int 15:290–295PubMedCrossRefGoogle Scholar
  22. 22.
    Compston JE, Greer S, Skingle SJ, Stirling DM, Price C, Friend PJ, Alexander G (1996) Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol 25:715–718PubMedCrossRefGoogle Scholar
  23. 23.
    Floreani A, Fries W, Luisetto G, Burra P, Fagiuoli S, Boccagni P, Della Rovere GR, Plebani M, Piccoli A, Naccarato R (1998) Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg 4:311–319PubMedCrossRefGoogle Scholar
  24. 24.
    Hay JE, Dickson ER, Weisner RH, Kron RAF (1990) Long-term effect of orthotopic liver transplantation on the osteopenia of primary biliary cirrhosis (abstract). Hepatology 12:838Google Scholar
  25. 25.
    Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F (1995) Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 57:15–19PubMedCrossRefGoogle Scholar
  26. 26.
    Watson RG, Coulton L, Kanis JA, et al (1990) Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin. J Hepatol 11:354–358PubMedCrossRefGoogle Scholar
  27. 27.
    Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S (1990) Osteoporosis and skeletal fractures in chronic liver disease. Gut 31:82–87PubMedGoogle Scholar
  28. 28.
    McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AG, Evans RA, McCaughan GW (1991) Bone loss after liver transplantation. Hepatology 14:613–619PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen A, Ebeling P, Sprague S, Shane E (2003) Transplantation osteoporosis. In: Favus MJ (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 370–379Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Pietra Pennisi
    • 1
  • Andrea Trombetti
    • 1
  • Emiliano Giostra
    • 2
  • Gilles Mentha
    • 2
  • René Rizzoli
    • 1
  • Carmelo E. Fiore
    • 3
  1. 1.Service of Bone Diseases [WHO Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and GeriatricsUniversity Hospital of GenevaGeneva 14Switzerland
  2. 2.Service of Transplantation, Department of SurgeryUniversity Hospital of GenevaGeneva 14Switzerland
  3. 3.Clinica Medica OVEUniversity of CataniaCataniaItaly

Personalised recommendations